Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
Luppi
M
M
Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy. mluppi@unimore.it
Barozzi
P
P
Potenza
L
L
Riva
G
G
Morselli
M
M
Torelli
G
G
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification / Q000472:pathogenicity*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin